Bank of America Raises Johnson & Johnson Price Target to $227, Citing MedTech Strength and Manageable Legal Risks
Bank of America has increased its price target for healthcare giant Johnson & Johnson to $227, highlighting its defensive investment profile and growth in MedTech, while downplaying the financial impact of ongoing talc litigation.